This is a working overview of Aib substitution, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-07. Anything still debated is marked as such rather than presented as settled.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
== High-molecular-weight DNA extraction method == In this method, plant nuclei are isolated by physically grinding tissues and reconstituting the intact nuclei in a unique Nuclear Isolation Buffer (NIB). The plastid DNAs are released from organelles and eliminated with an osmotic buffer by washing and centrifugation. The purified nuclei are then lysed and further cleaned by organic extraction, and the genomic DNA is precipitated with a high concentration of CTAB. The highly pure, high molecular weight gDNA is extracted from the nuclei, dissolved in a high pH buffer, allowing for stable long-term storage.
physical chemistry The branch of chemistry that studies chemical systems in terms of the principles, practices, and concepts of physics, such as motion, energy, force, time, thermodynamics, chemical equilibrium, and statistical mechanics, among others. In contrast to chemical physics, physical chemistry is predominantly (though not entirely) a macroscopic science that studies the physical and chemical interactions of bulk quantities of matter.
Throughout the 1850s, the sectional conflict regarding slavery was further inflamed by national legislation in the U.S. Congress and decisions of the Supreme Court. In Congress, the Fugitive Slave Act of 1850 mandated the forcible return to their enslavers in the South of persons taking refuge in non-slave states, while the Kansas–Nebraska Act of 1854 effectively gutted the anti-slavery requirements of the Missouri Compromise. In its Dred Scott decision of 1857, the Supreme Court ruled against an enslaved person brought into non-slave territory, simultaneously declaring the entire Missouri Compromise to be unconstitutional. These and other events exacerbated tensions between North and South that would culminate in the American Civil War (1861–1865). Beginning with South Carolina, 11 slave-state governments voted to secede from the United States in 1860–1861, joining to create the Confederate States of America. All other state governments remained loyal to the Union. War broke out in April 1861 after the Confederacy bombarded Fort Sumter. Following the Emancipation Proclamation on January 1, 1863, many freed slaves joined the Union army. The war began to turn in the Union's favor following the 1863 Siege of Vicksburg and Battle of Gettysburg, and the Confederates surrendered in 1865 after the Union's victory in the Battle of Appomattox Court House.
== Research == Quadrupole theory (stability, acceptance and transmission of multipole RF and electrostatic driven devises), molecular gas dynamics, and supersonic beam expansion into vacuum. Development of the DRC Collision/reaction cell. Development of mass spectrometry (CyTOF), including fundamentals of operation and design of different MS instrumentation.
Sources: en.wikipedia.org
=== April === 1 April: The minimum wage rises by 1.5% from $23.15 to $23.50. In addition, training and starting wages rise to $18.80. The Queenstown Lakes District Council strips Councillor Niki Gladding of her roles after she leaked plans by the Council to dump treated effluent into the Shotover River. 3 April – The New Zealand Parliament passes legislation repealing Section 7AA of the Oranga Tamariki Act 1989, which requires Oranga Tamariki (the Ministry of Children) to work in partnership with Māori iwi (tribes) and hapū (sub-groups). 4 April: The Financial Markets Authority commences civil proceedings against insurance company IAG New Zealand for overcharging about 239,000 customers $35 million by incorrectly pricing premiums over the past two decades. The New Zealand Parliament's Justice select committee recommends that the ACT party's contentious Treaty Principles Bill not proceed further following substantial public feedback. The Royal New Zealand Navy's court of inquiry concludes that a series of human errors led to the sinking of HMNZS Manawanui (2019) in early October 2024. 6 April – Several Greenpeace New Zealand protesters occupy part of Port Taranaki to prevent an Indonesian ship carrying palm kernel from unloading. Police arrest four protesters. 7 April: A bomb threat leads to the disruption of proceedings at the Wellington and Palmerston North district courts.
== N == N-acetylaspartate (NAA) A molecule found predominantly in neurons, often measured via magnetic resonance spectroscopy as a marker of neuronal health and density. Narcolepsy A neurological disorder characterized by excessive daytime sleepiness, sudden sleep attacks, and sometimes cataplexy. It involves dysfunction in the brain's regulation of sleep–wake cycles. Nasal cavity The air passageway behind the nose that houses the olfactory epithelium, which contains sensory neurons responsible for detecting odors. Neocortex The largest part of the cerebral cortex, involved in higher-order brain functions such as sensory perception, motor commands, reasoning, and language. Neologism A newly coined word or expression. In neuropsychology, may refer to nonsensical or made-up words produced by individuals with certain types of aphasia. Neostriatum A subdivision of the basal ganglia comprising the caudate nucleus and putamen. It is involved in motor control and reward processing. Neural crest A group of embryonic cells that gives rise to various structures, including peripheral neurons, glia, and parts of the face and skull. Neural oscillation Rhythmic or repetitive electrical activity in the central nervous system, often observed as brain waves in EEG recordings. Neural plasticity The ability of the nervous system to change its structure and function in response to experience, injury, or development. Neural stem cell A self-renewing progenitor cell capable of generating neurons and glial cells.
=== til === tilactase (INN) Tilade tilarginine acetate (USAN) tilbroquinol (INN) tildipirosine (INN) tiletamine (INN) tilidine (INN) tiliquinatine (USAN) tiliquinol (INN) tilisolol (INN) tilivapram (USAN) tilmacoxib (USAN) tilmicosin (INN) tilnoprofen arbamel (INN) tilomisole (INN) tilorone (INN) tilozepine (INN) tilsuprost (INN) tiludronate (INN) tiludronic acid (INN)
Sources: en.wikipedia.org
NMD is used to protect the cell from producing harmful truncated proteins resulting from nonsense mutations. NMD has recently been found to impact cell differentiation of stem cells due to the decay of mRNA encoding factors. The NMD pathway differentiates premature termination codons (PTC) from normal stop codons by only attacking presliced mRNA strands. This means that the mRNA contains exons and introns in the strand. This is because the machinery for NMD recognizes exon-junctions complexes. Unlike translational termination, NMD utilizes many intermediate protein complexes to achieve mRNA decay. The initial step of NMD is the construction of the SURP complex. This complex is composed of 4 proteins: SMG-1, Upf1, eRF1, and eRF3 (SURF). The complex is formed when Upf1 binds to SMG-1, which then clamps onto the eRF1 and eRF3 termination complex. The SURF complex then associates with a downstream complex composed of Upf2, Upf3, and EJC to create a new complex: Decay-Inducing Complex (DECID). Upon the joining of the two complexes, the DECID complex dissociates eRF1, eRF3, and the ribosome. The new complex contains EJC, Upf2, Upf3, SMG-1, and a phosphorylated Upf1. The phosphorylated Upf1 protein attracts additional SMG proteins, which are in the endonuclease enzymatic family. The SMG protein then cleaves the mRNA strand near the premature stop codon. This event is essentially decapping the protective head group on the mRNA strand, which will cause the rest of the strand to be degraded by exosomes.
SIMS and FAB are quite similar. SIMS uses an ion beam, usually Ar+ or Cs+. FAB uses a neutral atom beam, usually Ar or Xe. For SIMS and FAB, if the matrix compound is more acidic than the analyte, then predominantly (M + H)+ forms formed, and conversely (M − H)−. Also possibly forming (M + Na)+, (M + K)+, etc, if the matrix is contaminated incidentally (adventitiously) by sodium, potassium, etc. Typical matrix materials include glycerol, thioglycerol, 3-nitrobenzyl alcohol, diethanolamine, triethanolamine, and dithiothreitol-dithioerythritol mixture. They are usually used to analyze polypeptides and oligonucleotides up to 20 kDa. MALDE uses a photon beam, usually the soft-UV 337 nm nitrogen laser. It can also use an infrared (IR) laser for direct analysis of samples contained in gels or thin-layer chromatography (TLC) plates. MALDE can analyze small polymers (~1 kDa), to oligosaccharides, oligonucleotides and polypeptides, antibodies, up to small proteins (~300 kDa). It is highly sensitive, requiring only femtomoles of sample. Desorption/ionization on silicon (DIOS) is similar to MALDE, but without the matrix. The sample is deposited directly on a nanostructured (porous silicon) surface and the sample desorbed directly from the nanostructured surface through the adsorption of laser light energy. DIOS has been used to analyze organic molecules, metabolites, biomolecules and peptides, and, ultimately, to image tissues and cells.
Superconductivity in the cuprates is considered unconventional and is not explained by BCS theory. Possible pairing mechanisms for cuprate superconductivity continue to be the subject of considerable debate and further research. Similarities between the low-temperature antiferromagnetic state in undoped materials and the low-temperature superconducting state that emerges upon doping, primarily the dx2−y2 orbital state of the Cu2+ ions, suggest that electron-phonon coupling is less relevant in cuprates. Recent work on the Fermi surface has shown that nesting occurs at four points in the antiferromagnetic Brillouin zone where spin waves exist and that the superconducting energy gap is larger at these points. The weak isotope effects observed for most cuprates contrast with conventional superconductors that are well described by BCS theory. In 1987, Philip Anderson proposed that superexchange could act as a high-temperature superconductor pairing mechanism. In 2016, Chinese physicists found a correlation between a cuprate's critical temperature and the size of the charge transfer gap in that cuprate, providing support for the superexchange hypothesis. A 2022 study found that the varying density of actual Cooper pairs in a bismuth strontium calcium copper oxide superconductor matched with numerical predictions based on superexchange. But so far there is no consensus on the mechanism, and the search for an explanation continues. Similarities and differences in the properties of hole-doped and electron-doped cuprates:
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.